Risk factors for neutropenia with lenalidomide plus dexamethasone therapy for multiple myeloma

被引：5
|
作者：
Mitani, Y. [1 ]
Usami, E. [2 ]
Kimura, M. [2 ]
Nakao, T. [2 ]
Okada, K. [2 ]
Matsuoka, T. [2 ]
Kokuryou, T. [1 ]
Yoshimura, T. [2 ]
Yamakawa, M. [1 ]
机构：
[1] Kohka Publ Hosp, Dept Pharm, 1256 Matsuo,Minakuchi Cho, Koka, Shiga 5280074, Japan
[2] Ogaki Municipal Hosp, Dept Pharm, Gifu, Japan
来源：
PHARMAZIE | 2016年 / 71卷 / 06期
关键词：
EFFICACY; SAFETY;
D O I：
10.1691/ph.2015.5888
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Neutropenia may develop as an adverse event in patients with multiple myeloma receiving lenalidomide (LEN) plus dexamethasone (DEX) therapy. In the present study, we examined the risk factors associated with grade 3/4 neutropenia during the first cycle of LEN plus DEX therapy. We observed that hemoglobin level (<= 8.5 g/dl) was a significant risk factor for grade 3/4 neutropenia during the first cycle of therapy (odds ratio: 19.40; 95% confidence interval: 2.68-141.00; p<0.01). Thus, our findings suggest that determining the hemoglobin level could be useful in the risk management for neutropenia in patients receiving LEN plus DEX therapy.
引用
收藏
页码：349 / 351
页数：3
相关论文
共 50 条
  • [21] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
    Dimopoulos, M. A.
    Oriol, A.
    Nahi, H.
    San-Miguel, J.
    Bahlis, N. J.
    Usmani, S. Z.
    Rabin, N.
    Orlowski, R. Z.
    Komarnicki, M.
    Suzuki, K.
    Plesner, T.
    Yoon, S. -S.
    Ben Yehuda, D.
    Richardson, P. G.
    Goldschmidt, H.
    Reece, D.
    Lisby, S.
    Khokhar, N. Z.
    O'Rourke, L.
    Chiu, C.
    Qin, X.
    Guckert, M.
    Ahmadi, T.
    Moreau, P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14): : 1319 - 1331
  • [22] Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
    Facon, T.
    Kumar, S.
    Plesner, T.
    Orlowski, R. Z.
    Moreau, P.
    Bahlis, N.
    Basu, S.
    Nahi, H.
    Hulin, C.
    Quach, H.
    Goldschmidt, H.
    O'Dwyer, M.
    Perrot, A.
    Venner, C. P.
    Weisel, K.
    Mace, J. R.
    Raje, N.
    Attal, M.
    Tiab, M.
    Macro, M.
    Frenzel, L.
    Leleu, X.
    Ahmadi, T.
    Chiu, C.
    Wang, J.
    Van Rampelbergh, R.
    Uhlar, C. M.
    Kobos, R.
    Qi, M.
    Usmani, S. Z.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (22): : 2104 - 2115
  • [23] Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
    Shinsuke Iida
    Takaaki Chou
    Shinichiro Okamoto
    Hirokazu Nagai
    Kiyohiko Hatake
    Hirokazu Murakami
    Toshiyuki Takagi
    Kazuyuki Shimizu
    Henry Lau
    Kenichi Takeshita
    Masaaki Takatoku
    Tomomitsu Hotta
    International Journal of Hematology, 2010, 92 : 118 - 126
  • [24] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
  • [25] Does lenalidomide plus dexamethasone improve outcome in patients with relapsed multiple myeloma?
    Madhav V Dhodapkar
    Dennis L Cooper
    Nature Clinical Practice Oncology, 2008, 5 : 372 - 373
  • [26] Lenalidomide plus dexamethasone demonstrates efficacy in the treatment of relapsed or refractory multiple myeloma
    不详
    FORMULARY, 2008, 43 (02) : 79 - 80
  • [27] Does lenalidomide plus dexamethasone improve outcome in patients with relapsed multiple myeloma?
    Dhodapkar, Madhav V.
    Cooper, Dennis L.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 372 - 373
  • [28] Erratum: Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
    Nikhil C Munshi
    Constantine Mitsiades
    Paul G Richardson
    Kenneth C Anderson
    Nature Clinical Practice Oncology, 2008, 5 : 493 - 493
  • [29] Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
    Iida, Shinsuke
    Chou, Takaaki
    Okamoto, Shinichiro
    Nagai, Hirokazu
    Hatake, Kiyohiko
    Murakami, Hirokazu
    Takagi, Toshiyuki
    Shimizu, Kazuyuki
    Lau, Henry
    Takeshita, Kenichi
    Takatoku, Masaaki
    Hotta, Tomomitsu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (01) : 118 - 126
  • [30] Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study
    Leleu, Xavier
    Hulin, Cyrille
    Lambert, Jerome
    Bobin, Arthur
    Perrot, Aurore
    Manier, Salomon
    Jaccard, Arnaud
    Montes, Lydia
    Karlin, Lionel
    Godmer, Pascal
    Chalopin, Thomas
    Slama, Borhane
    Chretien, Marie Lorraine
    Laribi, Karim
    Dingremont, Claire
    Roul, Christophe
    Mariette, Clara
    Rigaudeau, Sophie
    Macro, Margaret
    Mohty, Mohamad
    Touzeau, Cyrille
    Moreau, Philippe
    Avet-Loiseau, Herve
    Corre, Jill
    Facon, Thierry
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S33 - S33
12345